🇺🇸 omeprazole/sodium bicarbonate in United States

FDA authorised omeprazole/sodium bicarbonate on 21 December 2004 · 232 US adverse-event reports

Marketing authorisations

FDA — authorised 21 December 2004

  • Application: NDA021706
  • Marketing authorisation holder: SANTARUS
  • Local brand name: ZEGERID
  • Indication: FOR SUSPENSION — ORAL
  • Status: approved

Read official source →

FDA — authorised 27 February 2006

  • Application: NDA021849
  • Marketing authorisation holder: SALIX
  • Local brand name: ZEGERID
  • Indication: CAPSULE — ORAL
  • Status: approved

Read official source →

FDA — authorised 24 March 2006

  • Application: NDA021850
  • Marketing authorisation holder: SANTARUS
  • Local brand name: ZEGERID
  • Indication: TABLET, CHEWABLE — ORAL
  • Status: approved

Read official source →

FDA — authorised 19 April 2013

  • Application: ANDA079182
  • Marketing authorisation holder: STRIDES PHARMA INTL
  • Status: supplemented

FDA — authorised 6 December 2016

  • Application: ANDA207476
  • Marketing authorisation holder: SCIEGEN PHARMS
  • Status: supplemented

FDA — authorised 30 April 2020

  • Application: ANDA212587
  • Marketing authorisation holder: ANDA REPOSITORY
  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Chronic Kidney Disease — 40 reports (17.24%)
  2. Fatigue — 29 reports (12.5%)
  3. Nausea — 25 reports (10.78%)
  4. Drug Ineffective — 24 reports (10.34%)
  5. Renal Failure — 24 reports (10.34%)
  6. Diarrhoea — 21 reports (9.05%)
  7. Headache — 18 reports (7.76%)
  8. Acute Kidney Injury — 17 reports (7.33%)
  9. Death — 17 reports (7.33%)
  10. Pain — 17 reports (7.33%)

Source database →

Other Gastroenterology approved in United States

Frequently asked questions

Is omeprazole/sodium bicarbonate approved in United States?

Yes. FDA authorised it on 21 December 2004; FDA authorised it on 27 February 2006; FDA authorised it on 24 March 2006.

Who is the marketing authorisation holder for omeprazole/sodium bicarbonate in United States?

SANTARUS holds the US marketing authorisation.